ANVS Share Price Performance
US$3.50
-1.58 (-31.10%)
Price US$3.50
Share Pricen/a
Annovis Bio, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
ANVS Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Annovis Bio, Inc. Key Details
About ANVS
- Founded
- 2008
- Employees
- 12
- CEO
- WebsiteView website
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer’s disease, as well as in phase 3 to treat parkinson’s disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer’s disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
